Phase 2
Completed N=15
Effect of Lorcaserin on Cannabis Withdrawal and Self-administration
Source: ClinicalTrials.gov NCT03253926 ↗Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Jul 2022
Primary outcomePrimary: Cannabis Self-administration — 5.75; 9.2; 5.75; 7.5 puffs of cannabis chosen
Summary
In this study, the investigators are interested in testing how lorcaserin influences the effects of cannabis in a human laboratory model of cannabis use.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cannabis Self-administration |
5.75; 9.2; 5.75; 7.5 | — |
Eligibility Criteria
Inclusion Criteria
- Current cannabis use
- Able to give informed consent and perform study procedures
- Women practicing an effective form of birth control
- English speaking
Exclusion Criteria
- Presence of any clinically significant medical diagnoses
- History of heart disease and cardiac risk factors, severe chronic obstructive pulmonary disease, uncontrolled hypertension, or diabetes
- Current parole or probation
- Certain psychiatric diagnoses
- Current pregnancy or lactation
Data sourced from ClinicalTrials.gov (NCT03253926). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.